Category - News

Markets

HCW ups Verastem PT to $15 from $10

H.C. Wainwright raised its price target for Verastem (NASDAQ:VSTM) to $15 from $10 after the FDA approved Verastem’s lead product, Copiktra, as the first PI3K-delta and P13K-gamma inhibitor for the treatment of third...

September 25, 2018

Developments

Aurinia Pharma completes enrollment in Phase 3 AURORA trial for LN

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has completed enrollment for the Phase 3 AURORA trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus...

September 25, 2018

Developments

IntelGenx posts successful bioequivalence study results for RIZAPORT

IntelGenx (TSXV:IGX; OTCQX:IGXT) reported successful results from a bioequivalence study for RIZAPORT, its proprietary anti-migraine VersaFilm product, demonstrating that RIZAORT is bioequivalent to the U.S. reference...

September 24, 2018

Markets

HCW starts Krystal Biotech at buy; PT $32

H.C. Wainwright launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $32 price target. The stock closed at $16.88 on Sept 21. “We believe the company has the potential to become a leader in the...

September 24, 2018

Markets

HCW starts Nanobiotix SA at buy; PT €25

H.C. Wainwright initiated coverage of Nanobiotix SA (PSE:NANO) with a “buy” rating and price target of €25. The stock closed at €16.60 on Sept. 21. Nanobiotix is developing NBTXR3, a radio-enhancer, which can improve...

September 24, 2018

Developments

IntelGenx to Partner with Tilray to produce cannabis-infused oral film products

IntelGenx (TSX-V:IGX; OTCQX:IGXT) executed a non-binding letter of intent with Tilray (NASDAQ:TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis in anticipation of...

September 20, 2018

Markets

Roth ups IRadimed PT to $35 from $26

Roth Capital Partners raised its price target for IRadimed (NASDAQ:IRMD) to $35 from $26 after updating its forward financial forecasts. The stock closed at $31.40 on Sept. 19. IRadimed is the world’s first and...

September 20, 2018

Executive Moves

Vincent Gardès joins Truffle Capital’s biomed team as senior partner

Truffle Capital appointed Vincent Gardès to its biomed team as a senior partner, joining Dr. Philippe Pouletty, Alain Chevallier and Antoine Pau.

September 20, 2018

Executive Moves

Shawn Cross joins JMP healthcare investment banking division

JMP Group (NYSE:JMP) named Shawn Cross as a managing director in its healthcare investment-banking group with a focus on the biotechnology and biopharmaceutical sectors.

September 20, 2018

Developments

Profound Medical to present TULSA-PRO 3-year outcomes and BPH subgroup analysis

Three-year clinical outcomes and a subgroup analysis of benign prostatic hyperplasia (BPH) patients enrolled in Profound Medical’s (TSX:PRN; OTCQX:PRFMF) earlier Phase 1 safety and feasibility study of TULSA-PRO will be...

September 19, 2018

Category - News

Subscribe